The article by Etkin and Mathalon1 argues that electroencephalography (EEG) is an underused modality for biomarker development in psychiatry research and calls for its broader utilization. Etkin has disclosed that he receives salary and equity from Alto Neuroscience, a for-profit entity developing new medications using predictive biomarkers including EEG. I refer you to the Conflict of Interest Disclosures provided by the authors for more detail on these relationships. This commercial interest must be kept in mind when reading this article and some may think that such a conflict overshadows the scientific arguments presented. I considered this a major factor when evaluating this article but ultimately concluded that the arguments deserve to be considered on their merits.